SYK Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 11.84% compared to Stryker Corp.'s net margin of 12.68%. Stryker Corp.'s return on equity of 15.17% beat Boston Scientific Corp.'s return on equity of 12.55%.

Stryker Corp. has a consensus price target of $424.40, signalling upside risk potential of 11.62%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Boston Scientific Corp. has higher upside potential than Stryker Corp., analysts believe Boston Scientific Corp. is more attractive than Stryker Corp..

Stryker Corp. has a beta of 0.873, which suggesting that the stock is 12.679% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Stryker Corp. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.89%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 40.48% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $7.2B, which are larger than Boston Scientific Corp. quarterly revenues of $5.3B. Stryker Corp.'s net income of $849M is higher than Boston Scientific Corp.'s net income of $670M. Notably, Stryker Corp.'s price-to-earnings ratio is 45.27x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.85x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 11.84% compared to Stryker Corp.'s net margin of 15.47%. Stryker Corp.'s return on equity of 15.17% beat Globus Medical, Inc.'s return on equity of 10.08%.

Stryker Corp. has a consensus price target of $424.40, signalling upside risk potential of 11.62%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 18.3%. Given that Globus Medical, Inc. has higher upside potential than Stryker Corp., analysts believe Globus Medical, Inc. is more attractive than Stryker Corp..

Stryker Corp. has a beta of 0.873, which suggesting that the stock is 12.679% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

Stryker Corp. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.89%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 40.48% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $7.2B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Stryker Corp.'s net income of $849M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Stryker Corp.'s price-to-earnings ratio is 45.27x while Globus Medical, Inc.'s PE ratio is 29.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.85x versus 4.51x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 11.84% compared to Stryker Corp.'s net margin of 27.89%. Stryker Corp.'s return on equity of 15.17% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Stryker Corp. has a consensus price target of $424.40, signalling upside risk potential of 11.62%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.38%. Given that Intuitive Surgical, Inc. has higher upside potential than Stryker Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Stryker Corp..

Stryker Corp. has a beta of 0.873, which suggesting that the stock is 12.679% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Stryker Corp. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.89%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 40.48% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $7.2B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Stryker Corp.'s net income of $849M is higher than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Stryker Corp.'s price-to-earnings ratio is 45.27x while Intuitive Surgical, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.85x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 11.84% compared to Stryker Corp.'s net margin of 6.15%. Stryker Corp.'s return on equity of 15.17% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.

Stryker Corp. has a consensus price target of $424.40, signalling upside risk potential of 11.62%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.65 which suggests that it could grow by 3.95%. Given that Stryker Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Stryker Corp. is more attractive than Zimmer Biomet Holdings, Inc..

Stryker Corp. has a beta of 0.873, which suggesting that the stock is 12.679% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.

Stryker Corp. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.89%. Zimmer Biomet Holdings, Inc. offers a yield of 0.97% to investors and pays a quarterly dividend of $0.24 per share. Stryker Corp. pays 40.48% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $7.2B, which are larger than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. Stryker Corp.'s net income of $849M is higher than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, Stryker Corp.'s price-to-earnings ratio is 45.27x while Zimmer Biomet Holdings, Inc.'s PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.85x versus 2.38x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.